A pilot quality-of-life instrument for acne rosacea

J Am Acad Dermatol. 2007 Aug;57(2):213-21. doi: 10.1016/j.jaad.2007.01.048. Epub 2007 Apr 18.

Abstract

Background: No rosacea-specific quality-of-life (QOL) instrument exists.

Objective: We sought to develop a validated, reliable rosacea-specific instrument.

Methods: From 6 in-depth interviews, we composed 21 rosacea-specific items. These items and Skindex-29 were administered in a validation cohort (n = 59). Internal consistency reliability and reproducibility were measured with Cronbach's coefficient alpha and intraclass correlation coefficient, respectively. Responsiveness was assessed comparing baseline with 4- to 6-month responses. Construct validity was assessed with principal axes factor analyses. Discriminant validity was examined with an additional 38 patients comparing differences in responsiveness between the rosacea-specific QOL instrument and Skindex.

Results: Reliability was high (Cronbach's alpha: 0.82-0.97, intraclass correlation coefficient: 0.70-0.95). The rosacea-specific QOL instrument showed preliminary responsiveness for patients with improved disease (P <or= .05). Principal axes factor analyses correlated to hypothesized scales (r = 0.57-0.82). Discriminant validity was illustrated with greater differences in responsiveness using the rosacea-specific QOL instrument (P = .008).

Limitations: Potential selection bias and lack of generalizability was a limitation.

Conclusions: The rosacea-specific QOL instrument, RosaQoL, appears to be a reliable and valid QOL instrument and shows preliminary responsiveness for patients with improving rosacea.

Publication types

  • Evaluation Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Validation Study

MeSH terms

  • Adult
  • Factor Analysis, Statistical
  • Female
  • Humans
  • Male
  • Middle Aged
  • Pilot Projects
  • Quality of Life*
  • Reproducibility of Results
  • Rosacea / physiopathology*
  • Sickness Impact Profile*